Filing Details
MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
8k filedNASDAQ:MDGL
MADRIGAL PHARMACEUTICALS, INC. (MDGL) Reports Material Event to SEC
MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
At publication ·
What changed
MADRIGAL PHARMACEUTICALS, INC. (NASDAQ:MDGL) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Madrigal Pharmaceuticals filed a Form 8-K with the SEC on August 12, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing summary.
- The company's stock was trading at $536.20 with a market capitalization of $12.7 billion at the time of the disclosure.
Market Context
MADRIGAL PHARMACEUTICALS, INC.'s stock currently trades at $536.20 with a market capitalization of $12.7B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for MADRIGAL PHARMACEUTICALS, INC.'s stock.
All SEC filings for MADRIGAL PHARMACEUTICALS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MDGL Stock Page
Frequently Asked Questions
Where can I read MDGL's SEC filings?
Browse all filings on our MDGL SEC filings page.
What types of SEC filings does MADRIGAL PHARMACEUTICALS, INC. file?
Public companies like MADRIGAL PHARMACEUTICALS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.